Trastuzumab emtansine (T-DM1) exemplifies antibody-drug conjugate (ADC) design. Which pharmacological concept explains why T-DM1 causes less systemic toxicity than free emtansine (DM1)?
- A Trastuzumab clears emtansine from circulation before it distributes to normal tissues
- B DM1 is pharmacologically inactive until metabolically activated inside tumor cell lysosomes
- C DM1 (maytansinoid microtubule poison) is stably linked to trastuzumab and delivered specifically to HER2-overexpressing cells via receptor-mediated endocytosis; systemic exposure to free DM1 is minimized by stable linker chemistry ✓
- D HER2-overexpressing cells express specific emtansine activating enzymes absent in normal tissues
Explanation
T-DM1 (ado-trastuzumab emtansine) uses a stable thioether linker (SMCC linker) to conjugate emtansine (DM1, a potent tubulin-depolymerizing maytansinoid) to trastuzumab. After binding HER2-overexpressing cells, T-DM1 is internalized via receptor-mediated endocytosis; lysosomal degradation of the antibody portion releases the active DM1-lysine metabolite intracellularly. The stable linker prevents premature drug release in plasma, minimizing systemic exposure to the cytotoxin. The drug-to-antibody ratio (DAR, typically 3.5 for T-DM1) and linker stability are critical ADC design parameters balancing efficacy and tolerability. This targeted delivery achieves tumor drug concentrations 50-100x higher than normal tissues.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.